investment report Merck & Co. (MRK) business overview from merck.com and reuters.com competition
|
|
- Noreen Nash
- 8 years ago
- Views:
Transcription
1 investment report Merck & Co. (MRK) business overview from merck.com and reuters.com Merck & Co Inc (Merck) is a global pharmaceutical company that develops, manufactures, and markets a wide range of drugs and vaccines, the majority of which are available by prescription only. Merck s biggest drugs include Zocor, used for the treatment of atherosclerosis, Fosamax, for prevention of osteoporosis, Singulair, for treatment of chronic asthma and yearly allergies, Propecia, for treatment of male pattern hair loss, Proscar, a urology product for the treatment of benign prostate enlargement, and Cozaar and Vasotec, used for treatment of hypertension/heart failure. In addition, in 2006 the FDA has approved five new Merck drugs, the most of any pharmaceutical company this year, which will be available within the coming months. Merck sells its drugs to drug wholesalers and retailers, hospitals, clinics, governmental organizations, and managed health care providers. Merck s products also include vaccines. They offer Varivax, a live virus vaccine for the prevention of chickenpox and M-M-R II, which prevents measles, mumps and rubella. In September 2005, the FDA approved ProQuad, a vaccine that prevents chickenpox, measles, mumps, and rubella. Additionally, Merck produces Pneumovax, which prevents pneumonia, Recombivax HB, for hepatitis B prevention, and Zostavax, for shingles. More recently, Merck has developed the vaccine Gardasil for the prevention of cervical cancer by targeting different strains of HPV and has begun a national advertising campaign. Merck also enters into partnerships with other international drug companies in order to pioneer new research and facilitate the development of drugs throughout the world. The company also publishes unbiased health research for distribution to consumers. Currently, Richard T. Clark, who has been with the company since 2000, is Merck s president, chief executive officer and director. Clark became CEO in late 2004 and has helped to guide the company during the aftermath of the Vioxx withdrawal. competition competitor company description implications for MRK Pfizer Inc. (PFE) A Global, research-based pharmaceutical company. In 2006, Pfizer produced drugs like Zoloft, Lipitor, Celebrex, Viagra, Zyrtec, and Zithromax. Pfizer recently sold off its consumer health division, which manufactured OTC drugs and other products like: Listerine, Rogaine, Sudafed, Rolaids, Neosporin, Visine, Lubriderm, and Purell to Johnson & Johnson. It also has an animal health division. Offers more non-rx products than MRK. Pfizer s market cap is approximate twice that of Merck and has more cash available for R&D
2 Johnson & Johnson (JNJ) Bristol Meyers Squibb Co. (BMY) GlaxoSmithKline plc (GSK) AstraZeneca plc (AZN) Large corporation that owns more than 230 operating companies and produces a range of healthcare and OTC related products in three divisions: Consumer, Pharmaceutical, Medical Devices and Diagnostics. Some of J&J s widely recognized consumer products include: Neutrogena, Aveeno, Band-Aid, Motrin, Johnson s Baby, Tylenol, Stayfree, and Splenda. Key pharmaceutical products: Risperdal (treatment of schizophrenia), Procrit (stimulates RBC production), Ditropan XL (overactive bladder), and Ortho Evra (birth control patch). BMY, inc. produces pharmaceuticals and other healthcare related products through 3 major segments: Pharmaceuticals, Nutritionals, and Other Healthcare. Pharmaceutical revenues mainly come from drugs that trea cardiovascular, virology (esp. HIV), psychiatric infectious diseases and cancer. The Nutritionals segment focuses on the production of infant formulas and is mainly marketed to healthcare professionals. The Other Healthcare segment involves wound/skin care products and medical imaging devices. GSK has two main industry segments: Pharmaceuticals and Consumer Healthcare. Its main markets are USA, Europe and Japan. As of Dec. 2005, 18 products entered clinical trials for the first time. The company has a new focus on creating medicines and vaccines for diseases that affect the developing world. Key pharmaceuticals: Paxil, Advair (treats asthma), Flonaseand Levitra. Consumer products: Abreva, Nicorette, Polident, and Tums 97% of AZN s revenue made from sale of prescription pharmaceuticals. Its prescription drugs are focused on cardiovascular, gastrointestinal, neuroscience, oncology, respiratory inflammation and infection. Key pharmaceuticals: Crestor, Nexium, Arimidex, Seroquel, and Symbicort. Its products available in 100 countries and there are 29 products are currently in Phase III. Offers a wide range of consumer healthcare products w/ recognizable brand names. A wider product line than MRK but a smaller market cap. Consumer product segment offers the wider product line. Mostly focused on pharmaceuticals. AZN has many products in the pipeline which could problematic in the future. financials income statement Looking at the annual report showing data from the past three years, we see that from , sales increased from $22,485.9M to $22, 938.6M. Yet, from , it actually decreased to $22,011.9M. Having a decrease in sales is a bad sign because this is how the company makes their money. In
3 addition to that, net income has steadily declined from year to year, which leads to the EPS decreasing on a yearly basis. Moreover, the 5% decrease in sales was not accompanied by a significant decline in costs, further decreasing the already low gross profit margin. Within the pharmaceuticals industry, a good gross profit margin is around 40-50%, whereas Merck s decreased from 40% in 2003 to 34.8% in 2004 and to 33.5% in From all of this, it is still difficult to project whether or not 2006 will also see a decrease in sales and gross profit margin. However, the most recent 10-Q filings already show a slight decrease in sales and a significant increase in costs as compared to the same quarter in The most likely reason for this decline in sales is the negative image that was brought about by the lawsuits against Merck for their product Vioxx. Even with the recent news that the Vioxx lawsuits will not be turned into a class action suit, the situation for Merck does not seem promising: they are losing money, their image is bad, there are way too many lawsuits still withstanding, and income was decreasing even before the Vioxx controversy began (possibly due to greater competition by generics). From Google Finance balance sheet Between 2004 and 2005 Merck s total current assets increased by a great deal from $13,475.2M to $21,049.3M. Normally, this significant increase would be a good thing, but it is important to note that their investments have sharply decreased $5,619.2M. If the company is not investing as much as before, then it means that they are holding cash for a reason, most likely for lawsuits. Current liabilities have also increased in addition to long term debt. Normally, this would mean that the company is borrowing to grow, but with the slight increase in PP&E and the Vioxx situation, it shows that Merck is borrowing in order to be able to payoff the upcoming lawsuits. Stockholder equity, despite all of these factors, has increased by $628.4M, and because the goal of corporate finance is to increase shareholder wealth, this shows that there is still some life in this company.
4 From Google Finance statement of cash flows Since 2003, net income has been dropping yearly, a sign that the company s profitability has been on the decline. This is most likely due to the negative image Merck has received as a result of the Vioxx controversy. The money being brought in from continuing operations has also been dropped between 2004 and Merck managed to get money in 2005 only from investing activities but continued to lose money through financing activities. Finally, Cash and Cash Equities increased significantly from , but this seems to have been done intentionally (partially seen in the large sale of securities, subsidiaries, and other investments) so that Merck will be able to off lawsuits. This cash inflow from investing activities, in addition to the sale of investments and subsidiaries, slightly outpaces Merck s their new investments, leading to increased cash flow.
5 From Google Finance valuation Since Merck s stock hit an all-time low after it pulled its blockbuster drug Vioxx from the pharmaceutical market in late September 2004, the company has performed remarkably well over the past two years. The stock has appreciated from $27 to $44. Its 1-year goal of $46 a share has already been achieved this year, in late October 2006, although the stock price has stabilized in the high $44 range. The company s stock has rebounded under the new leadership of CEO Richard T. Clark, who assumed the company s top post after Merck pulled Vioxx and CEO Raymond Gilmartin resigned. The gradual climb of Merck s stock to pre-vioxx levels has occurred despite the fact that nearly 7,000 lawsuits surrounding the company s questionable drug are still pending. For the past three quarters Merck has surpassed earnings predictions, adding credibility to Clark s commitment to improve the firm s position.
6 Merck has a PE ratio of 19.29, which puts it in the middle of the range for the healthcare industry and towards the higher end for companies in other industries. One of Merck s major competitors, Pfizer, has a PE ratio of while another competitor, Sanovi-Aventis, has a PE ratio of This reflects that investors recognize the strides that Clark has made within the past years and the company s commitment to product innovation, demonstrated by the recent FDA approvals of five new Merck drugs in However, there is still some concern that the company s prospects for growth will be dampened down as Vioxx lawsuits go forward, potentially draining financial resources for continued research and development. key MRK comparison comparison implications for MRK metric to industry to S&P 500 PE Ratio Merck s PE ratio is approximately equal to that of its competitors, indicating that investors believe it will generate returns and are willing to pay more for MRK stock than for stock in companies in other industries. However, in the healthcare sector, investors are not as enthusiastic to invest EPS < 2 Merck s EPS is above that for all major industry competitors, which reveals that its stock generates the highest company earnings per share of stock. It also indicates that Merck has been profitable since EPS allocates company profits to each outstanding share of stock. PEG Merck s high PEG ratio indicates that the Ratio company has the potential to grow significantly based on this year s earnings and the ones projected for FY 2007.
7 Price to Book or Price to Equity Price to Sales 5.01 < Industry competitors range from 2 to just over 4, so Merck is at the high end with a price to book ratio of A high price to equity ratio reflects that investors value the company slightly higher than others in the healthcare sector, which is an interesting paradox considering it has a average PE ratio Merck has a higher PS ratio than both its industry competitors and the S&P 500, which reveals that the stock s per-share sales are relatively high when compared to its stock price. investment opportunities strong research pipeline Merck is an internationally recognized, innovative leader in drug research and development. Its pipeline includes a host of therapeutics targeting the following areas: arthritis, cancer, cardiovascular diseases, diabetes, infectious diseases, neurology and much more. Merck states that it currently has more new medicines and product candidates in its pipeline, in all three phases, than ever before. In fact, as of August 1, 2006, Merck had twenty-eight candidates in phase one, eighteen in phase two, four in phase three, and four under FDA review, two of which were recently approved. In alone, seven new products were approved by the FDA. Evidently, Merck has many promising drugs in its pipeline, which continues to expand. successful partnerships More than one-third of Merck s sales come from alliance products and patents. Since 1995, more than twenty new products have been launched as a result of joint ventures and licensing alliances. This fact attests to Merck s history of and ongoing participation in successful collaborations that promote groundbreaking research in medicine as well as in diagnostics and devices. For example, Merck recently announced its collaboration with Neuroptix Corporation for the detection of Alzheimer s Disease through the use of ocular scanning diagnostics. Merck continues to benefit from joint ventures such as these, which promote groundbreaking research in medicine, technology and product development. successful marketing strategies Merck is a huge competitor in the pharmaceutical industry. Its products are sold in most major markets, and in more than a hundred countries worldwide. The company has also developed successful marketing strategies to enhance brand recognition. Their newest and most aggressive marketing campaign is for their new vaccine Gardasil and its ability to prevent certain kinds of cervical cancer. saving plan Merck expects to save billion dollars by 2010, by minimizing costs. The company plans to redesign its manufacturing processes worldwide to streamline the manufacturing process.
8 investment risks Vioxx lawsuits In 2004, Merck withdrew VIOXX, a best-selling arthritis drug, from the market after studies found its potential to increase cardiac risk. As a result, Merck faces countless product liability lawsuits. In fact, Merck has set aside1.57 billion dollars for future legal costs, and so far, it has only been winning half of its cases with thousands left to go. These lawsuits, in addition to company papers and s suggesting Merck knew of VIOXX s potential to cause heart attacks before it began selling the drug in 1997, has decreased investor confidence. sluggish sales Despite the introduction of new products such as Januvia, which targets Type-2 Diabetes, Merck sales have been decreasing. Moreover, these sales are expected to decrease next year as well due to increasing generic competition and drugs going off patent. threat of generic drugs & lack of diversification Like all large pharmaceutical companies, Merck struggles to compete with generic drugs. Each time Merck drugs lose their patent-protections, generic drugs take over the market, and thus sales decrease rapidly. For example, after Merck s highly successful, cholesterol drug Zocor lost its patent-protetion in June, its sales dropped 65%. Generic drugs pose as one of, if not the greatest, risks in the pharmaceutical industry. Because Merck s strategy has been to rely on the sale of a few blockbuster drugs for the majority of its revenue, increasing generic sales will lead to a significant reduction in sales, and thus revenue, if the company does not diversify its product base. If Congress decides to shorten patent-protection terms, then Merck will (like its competitors) struggle to pay the costs of research and development of its products.
The Industry. Johnson and Johnson is involved in the health care industry. through three distinct business segments: consumer, medical, and
1 Johnson and Johnson Analysis Andrew West and The Industry Johnson and Johnson is involved in the health care industry through three distinct business segments: consumer, medical,
More informationPharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch
Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry
More informationMedia Contact: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185
News Release Media Contact: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Merck Reports Double-Digit Earnings-Per-Share Growth for Second Quarter 2007 Second-Quarter 2007 Earnings
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationThe Origins of the Doughnut Hole: Excess Profits on Prescription Drugs
Issue Brief August 2006 The Origins of the Doughnut Hole: Excess Profits on Prescription Drugs BY DEAN BAKER The Medicare drug benefit was not designed in a way to minimize costs to the government and
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationJohnson & Johnson (JNJ) : Company Profile and SWOT Analysis
Brochure More information from http://www.researchandmarkets.com/reports/2193025/ Johnson & Johnson (JNJ) : Company Profile and SWOT Analysis Description: Synopsis 'Johnson & Johnson (JNJ) : Company Profile
More informationPrivate companies with strong growth in the healthcare sector offer interesting investment opportunities at attractive valuations.
Letter from the Chairman of the Board of Directors and the Management 7 Dear Shareholders HBM Healthcare Investments can look back at a successful financial year, which closed with a profit of CHF 67 million.
More informationFinancial Section. Financial Review. Contents
Financial Section Contents Financial Review Description of Merck s Business 20 Overview 20 Voluntary Product Withdrawal 21 Competition and the Health Care Environment 21 Operating Results 22 Selected Joint
More informationFOR IMMEDIATE RELEASE Media Contacts: Lainie Keller Investor Contacts: Teri Loxam (908) 236-5036 (908) 740-1986 (908) 740-1801 (908) 740-1879
News Release FOR IMMEDIATE RELEASE Media Contacts: Lainie Keller Investor Contacts: Teri Loxam (908) 236-5036 (908) 740-1986 Steven Cragle Justin Holko (908) 740-1801 (908) 740-1879 Merck Announces Fourth-Quarter
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationPharmaceutical Report Royalty Purchasing Industry. Thomas R. Wells
Pharmaceutical Report Royalty Purchasing Industry Thomas R. Wells Table of Contents Industry Overview 2 How Transactions Work 2 Advantages & Disadvantages for Inventors and Investors 4 Major Investors
More informationFirst Quarter 2015 Earnings Teleconference. April 28, 2015
First Quarter 2015 Earnings Teleconference April 28, 2015 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information Our discussions
More informationSPHERIX INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationPRESCRIPTION MEDICINES: COSTS IN CONTEXT
PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise
More informationHerzogenaurach, Germany, July 27, 2004 PUMA AG announces its consolidated nd
P Quarter P Half-Year For immediate release MEDIA CONTACT: INVESTOR CONTACT: U.S.A.: Lisa Beachy, Tel. +1 617 488 2945 Europe: Ulf Santjer, Tel. +49 9132 81 2489 Dieter Bock, Tel. +49 9132 81 2261 Herzogenaurach,
More informationTheravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:
More informationFOSSIL GROUP, INC. REPORTS THIRD QUARTER 2014 RESULTS. Third Quarter Net Sales Increase 10% to $894 Million; Diluted EPS Increases 24% to $1.
FOSSIL GROUP, INC. REPORTS THIRD QUARTER RESULTS Third Quarter Net Sales Increase 10% to $894 Million; Diluted EPS Increases 24% to $1.96 Updates Full Year Guidance and Provides Fourth Quarter Guidance
More informationINTERIM REPORT, 1 January - 30 June 2003
PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationFinancial Performance
Fundamental Value: $5.27 Market Price: $11.71 1 52 Week Range: $3.40 to $11.78 Recommendation: SELL 2 Symbol: JMMB Shares Outstanding: 1,463,386,752 units Market Value of Shares Outstanding: $17,136,258,865.92
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationFOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.
FOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.00 Fiscal Year 2014 Net Sales Increase 8% to $3.510 Billion;
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt Stock Exchange (DAX30): FRE US ADR program (OTC): FSNUY wwww.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationFY2009 Consolidated Results
FY2009 Consolidated Results (Fiscal year ended March 31, 2010) Sony Corporation 1 Operating income of 31.8 billion yen was achieved, compared to an operating loss in the previous fiscal year. The Financial
More informationVioxx Lawsuits and the Effect of Changes in Market Value
Product Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx. Kurt W. Rotthoff Stillman School of Business Seton Hall University January 2009 ABSTRACT Merck & Co., Inc. pulled Vioxx, a $2.5
More informationBrain J. Dunn, CEO Richfield, Minnesota U.S Latest fiscal year: 2010 Best Buy is an American retailer that sells a wide variety of electronic
Current Shareholders in Best Buy should hold their stock until price increases, and new investors should not invest if looking for fast money, Best Buy s stock may not more until more economic growth occurs.
More information6. Do you have an Advance Directive or Living Will? Yes No These are written statements about how you want to be treated if you get very sick.
Adult Health History Name: First Last Name you like to be called: Today s Date: Date of Birth: Male Female Transgender Male to Female Transgender Female to Male Other Filling out this form Answering these
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationQuality Affordable Healthcare Products. Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013
Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company July 31, 2013 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or
More informationPharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366
Pharmaceutical Business Plan Dawn Romvari-Mihalyi Cellular 917-208-7366 1.0 Executive Summary 2.0 Situation Analysis 2.1 Market Summary 2.1.1 Market Demographics 2.1.2 Market Needs 2.1.3 Market Trends
More informationinvestment report Ameritrade Holding Corporation (AMTD) business overview From Reuters.com competition
investment report Ameritrade Holding Corporation (AMTD) business overview From Reuters.com Ameritrade Holding Corporation is a provider of securities brokerage services and technology-based financial services.
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationNet Sales. Cost of Sales, Selling, General & Administrative Expenses, and Operating Income
Net Sales In the fiscal year ending March 31, 2002 (fiscal 2001), the Fujitsu Group faced a difficult global economic environment, with the impact of the slowdown in the U.S. economy reverberating throughout
More informationNews Release INVESTOR AND MEDIA CONTACT: George R. Kirkland Senior Vice President and Treasurer Phone: (229) 873-3830 gkirkland@sgfc.
Southwest Georgia Financial Corporation 201 First Street S.E. Moultrie, GA 31768 PH: (229) 985-1120 FX: (229) 985-0251 News Release INVESTOR AND MEDIA CONTACT: George R. Kirkland Senior Vice President
More informationMonster Worldwide Reports Third Quarter 2015 Results
Monster Worldwide Reports Third Quarter 2015 Results Third Quarter Financial Highlights: o Company Exceeds Expectations on All Profitability Metrics For the 5th Consecutive Quarter Adjusted EBITDA Including
More informationFinancial Analysis Project. Apple Inc.
MBA 606, Managerial Finance Spring 2008 Pfeiffer/Triangle Financial Analysis Project Apple Inc. Prepared by: Radoslav Petrov Course Instructor: Dr. Rosemary E. Minyard Submission Date: 5 May 2008 Petrov,
More informationQ3 2015 Financial Results and Corporate Update. November 4, 2015
Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking
More informationMGC Diagnostics Corporation Reports Fiscal Year 2015 Financial Results
MGC Diagnostics Corporation 350 Oak Grove Parkway Saint Paul, MN 55127 Telephone: (651) 484-4874 Facsimile: (651) 484-4826 FOR IMMEDIATE RELEASE MGC Diagnostics Corporation Reports Fiscal Year 2015 Financial
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationA LEADING GLOBAL HEALTHCARE COMPANY
A LEADING GLOBAL HEALTHCARE COMPANY Roadshow Boston March 2, 2016 Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains
More informationFinancial Statement and Cash Flow Analysis
Chapter 2 Financial Statement and Cash Flow Analysis Answers to Concept Review Questions 1. What role do the FASB and SEC play with regard to GAAP? The FASB is a nongovernmental, professional standards
More informationAstraZeneca PLC THIRD QUARTER AND NINE MONTHS RESULTS 2012
AstraZeneca PLC THIRD QUARTER AND NINE MONTHS RESULTS 2012 London, 25 October 2012 As expected, the revenue decline in the third quarter reflected the ongoing effect from the loss of exclusivity on several
More informationBreakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationDiluted net income per share (Yen) 90.03 129.05. Net assets per share assets. Equity
Summary of Consolidated Financial Results for the Nine months Ended December 31, 2008 February 3, 2009 Listed company name : Sysmex Corporation Code : 6869 Listed stock exchanges : Tokyo Stock Exchange
More informationThe NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005
EMBARGOED FOR RELEASE 6 p.m. EST, June 2 Summary The NSAID Drugs Prescriptions and Prices 2004 through 1 st Quarter 2005 An Analysis by Consumers Union and Consumer Reports Best Buy Drugs June 2005 Doctors
More informationHow To Calculate Financial Leverage Ratio
What Do Short-Term Liquidity Ratios Measure? What Is Working Capital? HOCK international - 2004 1 HOCK international - 2004 2 How Is the Current Ratio Calculated? How Is the Quick Ratio Calculated? HOCK
More informationIntel Reports Fourth-Quarter and Annual Results
Intel Corporation 2200 Mission College Blvd. P.O. Box 58119 Santa Clara, CA 95052-8119 CONTACTS: Reuben Gallegos Amy Kircos Investor Relations Media Relations 408-765-5374 480-552-8803 reuben.m.gallegos@intel.com
More informationSummary of Business Report for the Fifth Fiscal Year ended December 31, 2012
February 15, 2013 Summary of Business Report for the Fifth Fiscal Year ended December 31, 2012 RaQualia Pharma Inc. (4579, Osaka Stock Exchange, Growth Market) today reported financial results for the
More informationPfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?
Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor
More informationMouwasat Medical Services Company - Mouwasat
Recommendation Overweight Fair Value (SR) 92.00 Price as of 2 nd of March 2014 (SR) 81.75 Expected return 12.5% Company data Tadawul symbol 4002.SE 52- week high (SR) 94.00 52-week low(sr) 52.25 YTD change
More informationBusiness Risk Cash Flow Cushion Solvency Score Distance To Default Economic Moat Industry Group Sector
Morningstar Corporate Credit Research Novartis AG NOVN (XVTX) AA+ Business Risk Cash Flow Cushion Solvency Score Distance To Default Economic Moat Industry Group Sector Very Good Good Good Very Good Wide
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationChapter Seven STOCK SELECTION
Chapter Seven STOCK SELECTION 1. Introduction The purpose of Part Two is to examine the patterns of each of the main Dow Jones sectors and establish relationships between the relative strength line of
More informationRalph Lauren. Shelby Gray Group #2 BUS 440.02 11:30
Ralph Lauren Shelby Gray Group #2 BUS 440.02 11:30 0 COMPANY OVERVIEW Polo Ralph Lauren is a company specializing in the production of lifestyle products. Ralph Lauren began forty years ago with simply
More informationSiegfried when substance matters Semi-annual report 2008
Siegfried when substance matters Semi-annual report 2008 Key figures Continuing Operations 1 st Half-Year 2008 1 st Half-Year 2007 Difference Change in % Net sales (million CHF) 159.6 157.8 1.8 1.2 Net
More informationThe first quarter was highlighted by:
Mercantile Bank Corporation Reports Strong First Quarter 2013 Results Diluted earnings per share increased 79 percent Continued asset quality improvement and outlook remains positive GRAND RAPIDS, Mich.,
More informationACXIOM ANNOUNCES FIRST QUARTER RESULTS. Audience Operating System to Launch September 24 at AdWeek
For more information, contact: Katharine Boyce Acxiom Investor Relations 501-342-1321 investor.relations@acxiom.com EACXM ACXIOM ANNOUNCES FIRST QUARTER RESULTS Audience Operating System to Launch September
More informationThird-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015
Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,
More informationIntel Reports Second-Quarter Results
Intel Corporation 2200 Mission College Blvd. Santa Clara, CA 95054-1549 CONTACTS: Mark Henninger Amy Kircos Investor Relations Media Relations 408-653-9944 480-552-8803 mark.h.henninger@intel.com amy.kircos@intel.com
More informationExecutive Compensation and Governance Practices
Executive Compensation and Governance Practices April 2015 Executive Summary Transformative period for Bristol-Myers Squibb with continued evolution in 2014 - Ongoing strategic shift from a biopharmaceutical
More informationHTC CORPORATION 4Q15 BUSINESS REVIEW. CHIALIN CHANG, CFO & PRESIDENT OF GLOBAL SALES EDWARD WANG, VP OF FINANCE February 3, 2016
HTC CORPORATION 4Q15 BUSINESS REVIEW CHIALIN CHANG, CFO & PRESIDENT OF GLOBAL SALES EDWARD WANG, VP OF FINANCE February 3, 2016 DISCLAIMER STATEMENT This presentation and release contain forward-looking
More informationFIS Mergent Online. Walsh College Library. Select one or more of the databases to search
Walsh College Library FIS Mergent Online U.S. Company Data Financial information on over 25,000 U.S. public companies (active & inactive) International Company Data Financial information for over 20,000
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationusing the fully human ADLib system
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is
More informationWEYCO REPORTS THIRD QUARTER SALES AND EARNINGS
WEYCO REPORTS THIRD QUARTER SALES AND EARNINGS (Milwaukee, Wisconsin---November 4, 2014) Weyco Group, Inc. (NASDAQ:WEYS) (the Company ) today announced financial results for the quarter ended September
More information2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q
2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationMay 11 th, 2011 GMO CLOUD K.K. (Mothers of the Tokyo Stock Exchange3788)
Presentation of Financial Results for the First Quarter of Fiscal Year 2011 May 11 th, 2011 GMO CLOUD K.K. (Mothers of the Tokyo Stock Exchange3788) http://ir.gmocloud.com/. Notice concerning the handling
More informationPress release Regulated information
IBA TRADING UPDATE - THIRD QUARTER 2014 Louvain-La-Neuve, Belgium, 13 November 2014 - IBA (Ion Beam Applications S.A., EURONEXT), the world s leading provider of proton therapy solutions for the treatment
More informationBuy Sell and Short Your Way To Profits
Buy Sell and Short Your Way To Profits How to consistently make money in the stock market Biotech Sector Easiest and quickest place to make AND lose money Biotech stocks trade on HYPE and HOPE, the perfect
More informationManagement s Discussion and Analysis for 2014
1 Business Overview Industry total premiums as of December were 504 billion baht 1, a 13.75% increase over the same period of the previous year. They can be divided into first year premiums of 171 billion
More informationMuddy Waters Investment Competition. MBA Case Competition 2014 ZILLOW ACQUISITION OVER TRULIA ANALYSIS FULL PAPER
Muddy Waters Investment Competition MBA Case Competition 2014 ZILLOW ACQUISITION OVER TRULIA ANALYSIS FULL PAPER William Vidal Adriana Martins Raquel Clara W.A.R. Consultancy Team 1 Introduction This report
More informationThe Prize Fund for HIV/AIDS
The Prize Fund for HIV/AIDS A New Paradigm for Supporting Sustainable Innovation and Access to New Drugs for AIDS: De-Linking Markets for Products from Markets for Innovation May 26, 2011 Introduction
More informationFINANCIAL SUPPLEMENT December 31, 2015
FINANCIAL SUPPLEMENT December 31, 2015 Monster Worldwide, Inc. (together with its consolidated subsidiaries, the Company, Monster, we, our or us ) provides this supplement to assist investors in evaluating
More informationCOMPANY PROFILE. My recommendation for Paychex is a Buy/Hold.
Ticker: Sector: PAYX Information Technology Industry: Data Processing & Outsourcing Recommendation: Buy/Hold Pricing Closing Price $27.60 52-wk High $32.88 52-wk Low $24.65 Market Data Market Cap $9.97B
More informationProduct Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx (The Short Version)
Product Liability Litigation: An Issue of Merck and Lawsuits Over Vioxx (The Short Version) Kurt W. Rotthoff Stillman School of Business Seton Hall University Last working version, final version published
More informationManagement s Discussion and Analysis
Management s Discussion and Analysis 6 Financial Policy Sysmex regards increasing its market capitalization to maximize corporate value an important management objective and pays careful attention to stable
More informationLouise Mehrotra. Vice President Investor Relations
Louise Mehrotra Vice President Investor Relations Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These
More informationHalf Year 2015 Results
Half Year 2015 Results Letter to shareholders LifeWatch First Half Highlights Revenue growth of 9.1% to USD 52.5 million Above-market growth of over 12% in core monitoring services resulting in market
More informationCOLUMBUS, Georgia July 24, 2012 Aflac Incorporated today reported its second quarter results.
News Release FOR IMMEDIATE RELEASE AFLAC INCORPORATED ANNOUNCES SECOND QUARTER RESULTS, RAISES AFLAC JAPAN SALES OUTLOOK, AFFIRMS 2012 AND 2013 OPERATING EPS TARGETS, DECLARES THIRD QUARTER CASH DIVIDEND
More informationIncome Measurement and Profitability Analysis
PROFITABILITY ANALYSIS The following financial statements for Spencer Company will be used to demonstrate the calculation of the various ratios in profitability analysis. Spencer Company Comparative Balance
More informationIMPACT OF PATENT SETTLEMENTS ON DRUG COSTS: ESTIMATION OF SAVINGS
Providing key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. IMPACT OF
More informationINVESTMENT TRANSLATED INTO HUMAN WORDS
INVESTMENT JARGON TRANSLATED INTO HUMAN WORDS Hi, The world of finance loves jargon, but it s overly confusing. Let s clear the air. Here s a concise walk-through of terms that are common, but often not
More informationAn overview of FX Exposure Risk: Assessment and Management
An overview of FX Exposure Risk: Assessment and Management June 2015 1. Introduction This report presents an overview of various types of foreign currency exposure, their impact on the financial statements,
More informationSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K. GEOVAX LABS, INC. (Exact name of registrant as specified in its charter)
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):
More informationTHIRD QUARTER 2015 RECORD RESULTS REPORTED BY AMPHENOL CORPORATION
Amphenol News Release World Headquarters 358 Hall Avenue P. O. Box 5030 Wallingford, CT 06492-7530 Telephone (203) 265-8900 FOR IMMEDIATE RELEASE For Further Information: Craig A. Lampo Senior Vice President
More informationMedia Contact: Mike Conway Director, Corporate Communications Sherwin-Williams Direct: 216.515.4393 Pager: 216.422.3751 mike.conway@sherwin.
The Sherwin-Williams Company Reports First Quarter 2012 Financial Results Consolidated net sales increased 15.1% to a record $2.14 billion Diluted net income per common share increased 50.8% to a record
More informationGarmin Reports Best Quarter and Best Year in Company History, Announces Share Repurchase Program, Offers 2008 Guidance
INVESTOR CONTACT: Polly Schwerdt Phone 913/397-8200 E-Mail investor.relations@garmin.com MEDIA CONTACT: Ted Gartner Phone 913/397-8200 E-Mail media.relations@garmin.com Garmin Reports Best Quarter and
More informationMedivir s financial reports are available from its Website, www.medivir.se from these dates, under the Financial Information heading.
PRESS RELEASE, 23 October INTERIM REPORT, 1 January - 30 September In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310. CCS group divested to the Segulah II L.P. investment
More informationCase 25: Pfizer. Porsha Erwin Angel Harvey Curtis Hubbard DeMontrez Johnson Michael Kitchens China Thomas
Case 25: Pfizer Porsha Erwin Angel Harvey Curtis Hubbard DeMontrez Johnson Michael Kitchens China Thomas 1 Table of Contents History..Page 3 Summary..Page 3 General Environment Analysis.. Page 5 Industry
More informationWuXi PharmaTech Announces Second-Quarter 2014 Results
WuXi PharmaTech Announces Second-Quarter 2014 Results SHANGHAI, August 13, 2014 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving
More informationHow To Value A Stock
Chapter 9 Valuing Stocks 9-1. Assume Evco, Inc., has a current price of $50 and will pay a $2 dividend in one year, and its equity cost of capital is 15%. What price must you expect it to sell for right
More informationA guide to INVESTMENT TRUSTS. We ve been investing successfully since 1888. We re on the right course to invest for generations.
A guide to INVESTMENT TRUSTS We ve been investing successfully since 1888. We re on the right course to invest for generations. 2 A guide to Investment Trusts Contents 3 Investment Trusts explained 4 Differences
More informationPerformance Food Group Company Reports First-Quarter Fiscal 2016 Earnings
NEWS RELEASE For Immediate Release November 4, 2015 Investors: Michael D. Neese VP, Investor Relations (804) 287-8126 michael.neese@pfgc.com Media: Joe Vagi Manager, Corporate Communications (804) 484-7737
More informationFurther Developments of Hong Kong s Offshore RMB Market: Opportunities and Challenges
Further Developments of Hong Kong s Offshore RMB Market: Opportunities and Challenges Zhang Ying, Senior Economist In recent years, as the internationalization of the RMB has been steadily carrying out,
More informationQ1 FY2004 Consolidated Results
Q1 FY2004 Consolidated Results (Quarter Ended June 30, 2004) Sony Corporation Investor Relations 1 Statements made in this presentation with respect to Sony s current plans, estimates, strategies and beliefs
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More information